Protox, a pharmaceutical manufacturer that is developing botulinum toxin (Botox), announced on the 16th that it held a shareholder meeting at a bio-production plant located in Hyangnam Pharmaceutical Industrial Complex in Hwaseong, Gyeonggi-do.

The meeting was held with Protox CEO Lee Dong-beom, new plant manager Lee Seung-jin, executives and employees, and Protox shareholders attending.At the meeting, a question-and-answer session on business strategies and management was also held, along with sharing the R&D status, future plans, factory status, vision and strategy of Botulinum toxin A drug developed by Protox.

A company official said, “As a result of non-clinical trials, we have confirmed significant results equal to or more than that of existing products, and we believe that it will have a positive impact on entering domestic and foreign markets.”

Reporter Yoo Hyun-suk, guspower@asiae.co.kr